Cytology, SurePath Liquid-Based Pap Test and Human Papillomavirus (HPV), High Risk with 16 and 18 Genotype by PCR, SurePath. (for routine co-testing in women over 30)
Also known as: GH REQUEST
Use
Provides co-testing for cervical cancer screening in women over 30 by combining cytologic (Pap) evaluation with high‑risk HPV detection—including specific genotyping for HPV‑16 and HPV‑18—via PCR in samples collected using the SurePath liquid‑based cytology system. Intended to identify cytologic abnormalities and presence of high‑risk HPV strains associated with cervical cancer and its precursors.
Special Instructions
Not provided.
Limitations
Sensitivity may be affected by specimen collection methods, stage of infection, and presence of interfering substances. Change effective as of October 21, 2024: see test code 2000136 for updated version.
Methodology
Not provided.
Biomarkers
Not provided.
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Not provided.
Other tests from different labs that may be relevant
